(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 173% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.18%.
Ac Immune Sa's revenue in 2026 is $5,397,530.On average, 6 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,650,982,388, with the lowest ACIU revenue forecast at $320,438,442, and the highest ACIU revenue forecast at $9,534,456,162. On average, 5 Wall Street analysts forecast ACIU's revenue for 2027 to be $8,816,698,266, with the lowest ACIU revenue forecast at $7,979,280,424, and the highest ACIU revenue forecast at $9,938,939,069.
In 2028, ACIU is forecast to generate $10,071,109,837 in revenue, with the lowest revenue forecast at $197,348,108 and the highest revenue forecast at $20,522,790,772.